COMP <GO>
TAK vs ABBV // EV/EBITDA & P/E VALUATION
Takeda Pharmaceutical Company Limited American (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: TAK 3
— ABBV 9
▲ EV/EBITDA & P/E VALUATION LEADER: TAK
LAST: $20.01 (-0.69%) • MKT CAP: $63.23B
valuation
21.0x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TAK VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TAK | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 70.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 29.00% | -19.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.0x | 33.3x | -12.30 | TAK | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | 3.47% | -1.26 | ABBV | /fcf-yield <GO> |
| Operating Margin | 13.90% | 24.60% | -10.70 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 6.90% | +4.00 | TAK | /net-margins <GO> |
| Revenue Growth (YoY) | -3.30% | 8.60% | -11.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.74 | 5.33 | -1.59 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.6 | 65.1 | -8.50 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 1.15 | -0.09 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.5x | 113.1x | -82.60 | TAK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $63.23B | $513.86B | -$450.63B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TAK REV | ABBV REV | TAK GROSS % | ABBV GROSS % | TAK FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $61.16B | — | 70.2% | — | $17.82B |
| FY 2024 | — | $56.33B | — | 70.0% | — | $17.83B |
| FY 2023 | — | $54.32B | — | — | — | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TAK // BETA 1.06
ABBV // BETA 1.15